BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Vitamin E
,
rs2230926
,
FXYD4
,
calcium channel activity
,
Diabetes mellitus
,
Pancreas
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
interleukin- 22
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Two faces: IL-22 effects prevail over defense against metastasis.
IL-22 as a target for therapeutic intervention: Current knowledge on its role in various diseases.
Interleukin-22/Interleukin-22 binding protein axis and oral contraceptive use in polycystic ovary sy…
Role of Interleukin-22 in ulcerative colitis.
IL-22: Immunity's bittersweet symphony.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo
Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), …
The Role of IL-22/IL-22BP Axis in Atopic Dermatitis
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ